MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

4.95 4.43

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.72

Max

5.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	52M -42M
Darbuotojai	194
EBITDA	56M -39M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+74.67% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-13

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	44M 1.2B
Ankstesnė atidarymo kaina	0.52
Ankstesnė uždarymo kaina	4.95

Naujienos nuotaikos

By Acuity

50%

177 / 360 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-21 23:49; UTC

Pagrindinės rinkos jėgos

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026-01-21 21:12; UTC

Pagrindinės rinkos jėgos

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026-01-21 20:29; UTC

Pagrindinės rinkos jėgos

Chip Makers Gain After Trump Calls Off European Tariffs

2026-01-21 20:04; UTC

Pagrindinės rinkos jėgos

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026-01-21 23:34; UTC

Rinkos pokalbiai

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026-01-21 22:39; UTC

Uždarbis

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026-01-21 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-21 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-21 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026-01-21 21:19; UTC

Uždarbis

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026-01-21 20:45; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026-01-21 20:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026-01-21 20:31; UTC

Rinkos pokalbiai

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026-01-21 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026-01-21 20:27; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-21 20:27; UTC

Rinkos pokalbiai

Was It a 'TACO' Event? -- Market Talk

2026-01-21 20:26; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026-01-21 20:23; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026-01-21 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026-01-21 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Group Agrees to Buy Allfunds

2026-01-21 20:08; UTC

Uždarbis

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026-01-21 20:03; UTC

Rinkos pokalbiai

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026-01-21 19:51; UTC

Rinkos pokalbiai

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026-01-21 19:43; UTC

Rinkos pokalbiai

U.S. Ethanol Production Expected to Slip -- Market Talk

2026-01-21 19:31; UTC

Rinkos pokalbiai

Gold Settles at Fresh All-Time High -- Market Talk

2026-01-21 19:24; UTC

Uždarbis

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026-01-21 19:10; UTC

Rinkos pokalbiai

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026-01-21 18:57; UTC

Rinkos pokalbiai

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

74.67% į viršų

12 mėnesių prognozė

Vidutinis 8 USD 74.67%

Aukščiausias 9 USD

Žemiausias 7 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

177 / 360 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.